Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.36 |
| ▸ | POLA1 | P09884 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | CDK7 | P50613 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | CCNH | P51946 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7157730 | 0.86 | ALDH1A1 (0.42) | ALDH1A1KDM4ERXFP1CDK2PAK1 | |
| SCHEMBL11498403 | 0.84 | ALDH1A1 (0.50) | ALDH1A1KDM4ERXFP1CDK2PAK1 | |
| SCHEMBL9515925 | 0.81 | ALDH1A1 (0.41) | ALDH1A1KDM4ERXFP1CDK2PAK1 | |
| SCHEMBL1079075 | 0.80 | ALDH1A1 (0.49) | ALDH1A1KDM4ERXFP1CDK2PAK1 | |
| SCHEMBL10910405 | 0.79 | ALDH1A1 (0.45) | ALDH1A1KDM4ERXFP1CDK2PAK1 | |
| SCHEMBL8607904 | 0.78 | ALDH1A1 (0.41) | ALDH1A1KDM4ERXFP1CDK2PAK1 | |
| SCHEMBL460357 | 0.76 | ALDH1A1 (0.36) | ALDH1A1KDM4ERXFP1CDK2 | |
| SCHEMBL27658630 | 0.75 | ALDH1A1 (0.50) | ALDH1A1KDM4ERXFP1CDK2PAK1 | |
| SCHEMBL11200783 | 0.74 | ALDH1A1 (0.58) | ALDH1A1KDM4ERXFP1CDK2PAK1 | |
| SCHEMBL5138814 | 0.74 | ALDH1A1 (0.53) | ALDH1A1KDM4ERXFP1CDK2PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575971-A4 | PROCESS FOR THE PRODUCTION OF 3 -NUCLEOSIDE PRODRUGS | IDENIX CAYMAN LTD (KY) | 2008-03-05 | — | — | EP | claimed |
| EP-1283211-B1 | L-Nucleosides for the treatment of hepatitis B-virus and Epstein-barr virus | UNIV GEORGIA RES FOUND (US) | 2006-06-07 | — | — | EP | claimed |
| EP-1575971-A1 | PROCESS FOR THE PRODUCTION OF 3 -NUCLEOSIDE PRODRUGS | Idenix (Cayman) Limited (KY) | 2005-09-21 | — | — | EP | claimed |
| WO-2004058792-A1 | PROCESS FOR THE PRODUCTION OF 3'-NUCLEOSIDE PRODRUGS | IDENIX (CAYMAN) LIMITED (KY) | 2004-07-15 | — | — | WO | claimed |
| WO-1992017485-A1 | PREPARATION OF 3'-SUBSTITUTED-2',3'-DIDEOXYNUCLEOSIDES AND 2'-DEOXYNUCLEOSIDES FROM ACYCLIC, ACHIRAL PRECURSORS | EMORY UNIVERSITY (US) | 1992-10-15 | — | — | WO | claimed |
| US-20240216413-A1 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2024-07-04 | — | — | US | disclosed |
| EP-4319764-A2 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | Emory University (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4319762-A2 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | Emory University (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4319763-A2 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | Emory University (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4236961-A1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR TREATING PANCREATITIS, GLIOBLASTOMA, SARCOPENIA AND STROKE | Emory University (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022217155-A2 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022094435-A1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR TREATING PANCREATITIS, GLIOBLASTOMA, SARCOPENIA AND STROKE | EMORY UNIVERSITY (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2003010179-A1 | PROCESS FOR THE PREPARATION OF 2'-3'-DIDEOXY-2',3'-DIDEHYDRO-NUCLEOSIDES | EMORY UNIVERSITY (US) | 2003-02-06 | — | — | WO | disclosed |
| EP-1019034-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | Atherogenics, Inc. (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999001118-A9 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS INC (US) | 1999-05-20 | — | — | WO | disclosed |
| WO-1999001118-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS, INC. (US) | 1999-01-14 | — | — | WO | disclosed |
| EP-0831852-A1 | NUCLEOSIDES WITH ANTI-HEPATITIS B VIRUS ACTIVITY | EMORY UNIVERSITY (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040164-A1 | NUCLEOSIDES WITH ANTI-HEPATITIS B VIRUS ACTIVITY | EMORY UNIVERSITY (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040822-A1 | PREPARATION OF BIOLOGICALLY ACTIVE MOLECULES BY MOLECULAR IMPRINTING | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1992017485-A1 | PREPARATION OF 3'-SUBSTITUTED-2',3'-DIDEOXYNUCLEOSIDES AND 2'-DEOXYNUCLEOSIDES FROM ACYCLIC, ACHIRAL PRECURSORS | EMORY UNIVERSITY (US) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216413-A1 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | MTAP, NSUN3, METTL3 | ALDH1A1 2159/4885KDM4E 1062/4885RXFP1 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.